New ColdZyme Website – with a focus on science and understanding the common cold

Enzymatica is proud to launch a new website for ColdZyme, where we present the latest research and provide clear, educational information on how our medical device product can help shorten the duration of a common cold.

Colds are caused by viruses that infect the cells of the upper respiratory tract. ColdZyme works by forming a protective barrier in the throat, which can inhibit viruses from infecting cells and thereby reduce both symptoms and sick days.

Scientific evidence

On the new website, we highlight our most recent publication in the peer-reviewed journal The Journal of Physiology. Two independent research groups, at the University of Kent and the University of Vienna, have studied the effects of ColdZyme in complementary ways:

• Clinical trial – a randomised, double-blind, placebo-controlled study targeting active athletes. The results showed significantly lower symptom scores and fewer sick days among participants using ColdZyme.
• In vitro model – an advanced human airway model where ColdZyme demonstrated a clear effect in limiting viral spread.

The cold school

To deepen the understanding of colds, we have also developed The Cold School, where we explain the different phases of a cold and how the immune system responds. Here you can follow the process from the moment a virus enters the body to the immune system’s activation and defence against the infection.

Our goal

With this new website, we aim to provide both consumers and healthcare professionals with knowledge based on scientific evidence, clearly demonstrating how ColdZyme can play a role in managing colds.

Explore the new website here (in Swedish)